JP Morgan downgraded Carlyle Group from Overweight to Neutral and set a new price target of $44.00 from $46.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/12/2024 | $42.00 | Equal Weight | Wells Fargo |
| 8/27/2024 | $55.00 | Buy | Redburn Atlantic |
| 8/6/2024 | $46.00 → $44.00 | Overweight → Neutral | JP Morgan |
| 1/19/2024 | $40.00 → $41.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $42.00 | Market Perform | TD Cowen |
| 11/29/2023 | $32.00 | Outperform → In-line | Evercore ISI |
| 10/5/2023 | Peer Perform | Wolfe Research | |
| 5/19/2023 | $40.00 | Buy | Citigroup |
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Wednesday November 20, 2024, for its fourth quarter and full year 2024. CCIF will host a conference call at 10:00 a.m. EDT on Thursday, November 21, 2024, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally manage
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. EST on Wednesday, November 6, 2024 to announce its financial results for the third quarter ended September 30, 2024. A news release containing the quarterly results will be issued on Tuesday, November 5, 2024. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc. Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ:CGBD) business dev
Sale simplifies Advance's enterprise structure and sharpens focus on the blended box business Net proceeds to be used primarily to strengthen balance sheet and invest in the business Advance Auto Parts, Inc. (NYSE:AAP), a leading automotive aftermarket parts provider in North America that serves both professional installer and do-it-yourself customers, announced that it has entered into a definitive agreement to sell Worldpac, Inc., an automotive parts wholesale distribution business, to funds managed by global investment firm Carlyle (NASDAQ:CG) for $1.5 billion in cash. The transaction is expected to close before the end of the year. "We are pleased to announce the sale of the World
London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development. Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office. Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he
MCLEAN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Acentra Health, a technology solutions and clinical services company dedicated to helping government healthcare agencies accelerate better health outcomes, has named Brett Barton as Senior Vice President (SVP) of Client Experience. In this newly created role, Barton will represent the voice of the client across multiple touchpoints to deliver an exceptional experience that supports continued growth for the company and elevates the Acentra Health brand. Barton brings over three decades of experience in healthcare technology and services supporting the public sector and health and human services market. He comes to Acentra Health from Gainwell
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi
Ares Management Corp. (NYSE:ARES) and HPS Investment Partners are spearheading a $3 billion credit facility to finance Carlyle Group Inc.’s (NASDAQ:CG) potential acquisition of Baxter International Inc.’s (NYSE:BAX) kidney-care division. This debt package includes a $2.5 billion unitranche loan and a $450 million revolver. Oaktree Capital Management is also involved in the financing, and smaller lenders may participate after signing. Also Read: Medical Devices Giant Baxter Secures FDA Approval For New Infusion Pump System. The financing terms suggest an interest rate five percentage points above the Secured Overnight Financing Rate, placing the division Vantive’s leverage at 4.2
https://www.bloomberg.com/news/articles/2024-07-23/ares-hps-line-up-3-billion-debt-for-carlyle-s-baxter-unit-bid?sref=y3YMCJ4e
Directors Robert Langer and Stephen Berenson will also retire from the Board.
4 - Carlyle Group Inc. (0001527166) (Reporting)
3 - Carlyle Group Inc. (0001527166) (Reporting)
4 - Carlyle Group Inc. (0001527166) (Reporting)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)
PLANO, Texas, Oct. 24, 2024 /PRNewswire/ -- CorroHealth, a leading provider of revenue cycle management (RCM) solutions to health systems and health plans, announced it has signed definitive agreements for a strategic investment from Patient Square Capital (Patient Square), a dedicated health care investment firm. Current shareholders, including investment funds affiliated with global investment firm Carlyle (NASDAQ:CG), TT Capital Partners, Sanaka Group, and CorroHealth management, will remain investors, with Patient Square and Carlyle sharing joint control of CorroHealth. "
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund ("we," "us," "our," "CCIF" or the "Fund") (NYSE:CCIF) announced today that it will release financial results after market close on Wednesday November 20, 2024, for its fourth quarter and full year 2024. CCIF will host a conference call at 10:00 a.m. EDT on Thursday, November 21, 2024, to discuss the results. The conference call will be available via public webcast via a link on Carlyle Credit Income Fund's website at www.carlylecreditincomefund.com and will also be available on the website soon after the call's completion. About Carlyle Credit Income Fund Carlyle Credit Income Fund (NYSE:CCIF) is an externally manage
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. ("Carlyle Secured Lending") (NASDAQ:CGBD) will host a conference call at 11:00 a.m. EST on Wednesday, November 6, 2024 to announce its financial results for the third quarter ended September 30, 2024. A news release containing the quarterly results will be issued on Tuesday, November 5, 2024. The conference call will be available via public webcast via a link on Carlyle Secured Lending's website at carlylesecuredlending.com and will also be available on the website soon after the call's completion. About Carlyle Secured Lending, Inc. Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ:CGBD) business dev
N-PX - Carlyle Group Inc. (0001527166) (Filer)
13F-HR - Carlyle Group Inc. (0001527166) (Filer)
S-8 - Carlyle Group Inc. (0001527166) (Filer)
Wells Fargo initiated coverage of Carlyle Group with a rating of Equal Weight and set a new price target of $42.00
Redburn Atlantic initiated coverage of Carlyle Group with a rating of Buy and set a new price target of $55.00
JP Morgan downgraded Carlyle Group from Overweight to Neutral and set a new price target of $44.00 from $46.00 previously